Author Interviews, Heart Disease, Stroke / 03.04.2025

MedicalResearch.com Interview with: Sai Rahul Ponnana, M.S Advanced Data Analytics Research Analyst Cardiovascular Research Institute Case Western Reserve University School of Medicine Wolstein Research Building, Cleveland, OH. 44106-7288 MedicalResearch.com: What is the background for this study? Response: Microplastics are tiny plastic particles less than 5 mm which have become a pervasive environmental pollutant, detectable in air, water, food, and even human tissues. While their ecological impacts have been well-documented, their influence on human health, particularly cardiovascular health, remains underexplored. Recent mechanistic studies suggest that microplastics can induce inflammation, oxidative stress, and endothelial dysfunction, all of which are pathways implicated in chronic disease and ASCVD. In our study, we analyzed a total of 709 U.S. coastal census tracts to investigate the association between marine microplastic concentration data obtained from NOAA NCEI database and the prevalence of stroke and other chronic non-communicable diseases (NCDs) such as high blood pressure and diabetes, sourced from CDC places database. (more…)
Heart Disease, Technology / 28.03.2025

The Apple Watch ECG feature is a game changer in heart health screening and gives users an easy way to take a single lead ECG from their wrist. The ECG app on the Apple Watch uses an electrical heart sensor to detect the heart's electrical activity and identifies atrial fibrillation (AFib) early on – a condition that, if not treated, can lead to serious consequences including stroke. This is done through a simple process of launching the app and placing the finger on the digital crown for about 30 seconds and the users will have their heart rhythm categorized as normal, AFib, or inconclusive. The results can then be easily sent to healthcare providers through the Health app thus increasing the accessibility of health information.

Accuracy and Reliability

It has been established that the Apple Watch ECG is quite effective in its operation. Clinical studies have shown that the sensitivity of AFib detection using the Apple Watch is more than 98% and specificity is more than 99% compared to the traditional 12 lead ECGs. This high level of accuracy makes the device a good screening tool for the early detection of heart arrhythmias. It is crucial to identify AFib early as this gives patients a chance seek medical attention before complications occur. In this way, the Apple Watch not only provides convenience but also possible life-saving services.

(more…)
Heart Disease, Personalized Medicine / 27.03.2025

Sponsored post How we treat heart disease remains a major health concern in today's fast-pace world. More healthcare professionals are turning to personalized, prevention-based care as medical tools improve and our understanding of cardiovascular risk grows. An example of that change is interventional cardiologist Dr. Robert Marshall, who is known for his clinical expertise but also for his patient-centered approach. Building a Strong Foundation Dr. Marshall has spent years refining his approach to cardiology, combining traditional medical training with deep knowledge in nutrition. This background gives him a unique, holistic perspective when it comes to heart health. But what truly makes his care stand out is how he adapts his knowledge to fit the individual needs of each patient. (more…)
Author Interviews, Heart Disease, OBGYNE / 05.02.2025

MedicalResearch.com Interview with: Cande V. Ananth PhD MPH Professor and Vice Chair for Academic Affairs Chief, Division of Epidemiology and Biostatistics Department of Obstetrics, Gynecology, and Reproductive Sciences Rutgers Robert Wood Johnson Medical School, NJ Editor-in-Chief, Paediatric and Perinatal Epidemiology   MedicalResearch.com: What is the background for this study? Response: The rate of twin pregnancies worldwide has risen in recent decades, driven by fertility treatments and older maternal ages. MedicalResearch.com: What are the main findings? Response: Compared to singleton pregnancies with normal blood pressure, people with twins with normal blood pressure were around twice as likely to be hospitalized with cardiovascular disease. For those with twins with high blood pressure during pregnancy, the risk was more than eight times higher.  (more…)
Heart Disease, Legal-Malpractice, Women's Heart Health / 13.12.2024

Heart attacks are not just a male health issue. Every year, 30,000 women in the UK are admitted to hospital after having a heart attack. Despite this, women are 50% more likely than men to receive an incorrect initial diagnosis, delaying critical care. The most common heart attack symptom for both sexes is chest pain or discomfort that doesn’t subside. However, women often experience additional symptoms that can easily be missed, such as:
  • Pain radiating to the jaw, neck, back, stomach, or arms.
  • Nausea, dizziness, or feeling faint.
Clinicians unfamiliar with these gender-specific differences may misinterpret these symptoms as being unrelated to the heart. Tragically, women whose heart attacks are missed at first have a 70% higher risk of dying compared to those promptly diagnosed. (more…)
Author Interviews, COVID -19 Coronavirus, Heart Disease / 10.10.2024

MedicalResearch.com Interview with: Stanley Hazen, MD, PhD Chair, Cardiovascular & Metabolic Sciences Lerner Research Institute CoSection head, Preventive Cardiology & Cardiovascular Rehabilitation Heart, Vascular and Thoracic Institute Cleveland Clinic MedicalResearch.com: What is the background for this study? Response:  One of the unique features of COVID is that in some subjects, there unfortunately appear to be long term adverse effects that can occur following resolution of the acute infection.  These studies add to the growing body of data showing that COVID-19 infection can enhance risk for experiencing adverse cardiac events (heart attack, stroke, and death) over time. (more…)
Aging, Author Interviews, BMJ, Heart Disease, Statins / 11.09.2024

MedicalResearch.com Interview with: Borislava Mihaylova, DPhil Associate Professor & Senior Health Economist Nuffield Department of Population Health, University of Oxford, UK & Professor of Health Economics Wolfson Institute of Population Health Queen Mary University of London, UK MedicalResearch.com: What is the background for this study? Response: Despite high risks of heart disease and stroke in people over 70 years old and high need for preventive treatment such as statins, fewer older people use statins [compared to middle-aged people]. This, at least in part, is likely due to fewer older people, particularly those without previous heart attacks and strokes, included in the randomized studies of statin treatment. This has led to more limited evidence among them with larger uncertainty. Thus, we set to re-examine the value of statin treatment using the latest evidence and contemporary population data. (more…)
Author Interviews, Heart Disease, JAMA, Lipids / 03.07.2024

MedicalResearch.com Interview with: Evan A Stein MD PhD FACC COO/CSO LIB Therapeutics Cincinnati. OH USA 45227 MedicalResearch.com: What is the background for this study? Response: Cardiovascular disease (CVD) remains the main cause of morbidity and mortality worldwide and is increasing in rapidly industrializing countries and is projected to cause more than >20 million deaths annually over the next 15 years. Low-density lipoprotein cholesterol (LDL-C) is well established as a major, easily modifiable, risk factor for CVD. Reductions with statins and, more recently, PCSK9 inhibitors, all agents which directly or indirectly upregulate the LDL receptor and enhance LDL-C clearance, have demonstrated CVD event reductions in cardiovascular outcome trials. Extensive data from these trials, provide a rough estimate that every 40 mg/dL reduction in LDL-C will reduce the risk of major CV cardiovascular events by 22% to 24%. Furthermore, trials with PCSK9 inhibitors added to statins which achieve substantial additional LDL-C reduction show and CVD event reduction remains linear to very low LDL-C levels without signals of adverse events. Based on this body of evidence, recent revisions to national and international guidelines, now advocate for greater LDL-C reductions and lower LDL-C treatment goals, for patients not achieving these goals on statins alone. The current consensus target goal for LDL-C in patients with CVD, or who are at very-high risk for of CVD, is now less than <55 mg/dL, and <70 mg/dL for those at high risk. This global trial of over 900 patients with CVD, or at very or high risk for CVD, on maximally tolerated statins assessed the 52-week efficacy and safety of monthly lerodalcibep. (more…)
Author Interviews, Genetic Research, Heart Disease, Nature / 14.06.2024

MedicalResearch.com Interview with: Ben Omega Petrazzini, B.Sc. Associate Bioinformatician Ron Do Laboratory Ron Do, Ph.D. Professor, Department of Genetics and Genomic Sciences Director, Center for Genomic Data Analytics Associate Director in Academic Affairs, The Charles Bronfman Institute for Personalized Medicine Charles Bronfman Professor in Personalized Medicine Icahn School of Medicine at Mount Sinai     MedicalResearch.com: What is the background for this study? Response: Rare coding variants directly affect protein function and can inform the role of a gene in disease. Discovery of rare coding variant associations for coronary artery disease (CAD) to date have only had limited success. Genetic studies typically use standard phenotyping approaches to classify cases versus controls for CAD. However, this phenotyping approach doesn’t capture disease progression or severity in individuals. We recently introduced an in-silico score for CAD (ISCAD) that tracks CAD progression, severity, underdiagnosis and mortality (Forrest et al. The Lancet, 2023, PMID 36563696). ISCAD was built using a machine learning model trained on clinical data from electronic health records (EHR). Importantly, ISCAD is a quantitative score that measures CAD on a spectrum. The quantitative nature of the score provides an opportunity to discover additional rare coding variant associations that may not have been detected with the standard case-control phenotyping approach. Here in this study, we performed a large-scale rare variant association study in the exome sequences of 604,915 individuals for ISCAD, a machine learning-based score for CAD. (more…)
Author Interviews, Critical Care - Intensive Care - ICUs, Heart Disease, Kidney Disease, NEJM / 13.06.2024

MedicalResearch.com Interview with: Prof Giovanni Landoni, MD Associate Professor Università Vita-Salute San Raffaele Milan, Italy MedicalResearch.com: What is the background for this study? Response: Acute kidney injury (AKI) affects approximately 10-15% of hospitalized patients, and up to 50% of intensive care unit (ICU) patients. In cardiac surgery one patient out of three will face AKI during the postoperative period, and this will lead to higher morbidity and mortality. AKI is associated with an elevated risk of chronic kidney disease, as well as, in the most severe cases, with the use of renal replacement therapy, which may double hospitalization costs, reduce quality of life, and increase long-term mortality. So far, no preventive measure with level I of evidence did exist for AKI. The PROTECTION trial is a multinational, randomized, double-blind, placebo-controlled trial, conducted at 22 centers in 3 different countries. We recruited 3,511 adult patients undergoing cardiac surgery with cardiopulmonary bypass to receive an intravenous infusion of amino acids (AA) (Isopuramin 10%, Baxter), at 2g/kg/day up to a maximum 100g/day, or an equivalent dose of placebo (Ringer’s solution), for a maximum of 72 hours. The primary outcome was the incidence of any stage of AKI, according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 creatinine criteria. (more…)
ADHD, Author Interviews, Heart Disease, Stroke / 07.05.2024

MedicalResearch.com Interview with: Dr Anders Holt MD PhD Department of Cardiology Copenhagen University Hospital–Herlev and Gentofte Gentofte Hospitalsvej Hellerup, Denmark MedicalResearch.com: What is the background for this study? What types of ADHD treatments were in the study? Response: An increasing number of adults are being diagnosed with ADHD and subsequently treated. Taking the drugs' effect on the sympathetic nervous system into account, it seems relevant to investigate whether treatment could be associated with an elevated long-term risk of cardiovascular disease. The drugs included in the study were methylphenidate, atomoxetine, lisdexamfetamine, dexamfetamine, and modafinil. Owing to the fact that atomoxetine is not a sympathomimetic amine as the others, separate supplementary analyses were carried out for this drug, yielding similar results. (more…)
Heart Disease, Infections, Technology / 07.05.2024

MedicalResearch.com Interview with: Sarah Dräger, MD Postdoc, BRCCH Researcher Internal Medicine and ID specialist Division of Internal Medicine University Hospital Basel, Switzerland Basel   MedicalResearch.com: What is the background for this study? Response:In patients with severe infections and patients in the intensive care unit, therapeutic drug monitoring (TDM) may be used to optimize and personalize intravenous antibiotic treatment. In these patients, “conventional antibiotic dosing”, e.g. selection of the dose only considering the renal function and, if applicable, body weight, may lead to over- or underdosing due to an altered drug metabolism. This, in turn may be associated with worse clinical outcome or toxic side effects. TDM is used to monitor antibiotic blood plasma concentrations and provides guidance to the clinicians to adjust the antibiotic dosing according to the TDM results. But the collection of blood is an invasive, time- and resource-consuming sample collection technique and leads to discomfort to the patients. Additionally, turnaround time may be long (3h to 8h), and analyses may be offered only twice or three time a week. This may be too late to guide antibiotic dosing timely in patients with a very dynamic drug metabolism. Therefore, alternatives are required to overcome the limitations of current TDM. By using exhaled breath, we aim to develop an innovative therapeutic drug monitoring technique, which is non-invasive, easy to collect, not associated with discomfort to the patient, and which may allow to decrease the turnaround time, especially when combined with real-time analyses. (more…)
Author Interviews, Heart Disease, Technology / 03.04.2024

MedicalResearch.com Interview with: Dr. Janarthanan Sathananthan M.D. Chief Medical Officer for Interventional Cardiology Therapies Boston Scientific MedicalResearch.com: What is the background for this study? boston-scientificResponse: Despite significant improvements in the drug-eluting stents that are used to treat patients with coronary artery disease, 10% of the percutaneous coronary interventions (PCIs) in the U.S. today address in-stent restenosis (ISR), which is when a previously stented section of a coronary artery becomes obstructed or narrowed by plaque or scar tissue. These patients require additional intervention to avoid potential complications. In the multicenter, randomized AGENT IDE trial, we evaluated whether the AGENT™ Drug-Coated Balloon (DCB), a balloon catheter coated with anti-restenotic paclitaxel, is superior to an uncoated balloon in patients for treating ISR. The AGENT DCB is currently available in countries outside the U.S. Our goal is to bring this technology to market in the U.S. and finally provide physicians with an alternative to traditional ISR treatments, such as placing additional layers of stents or radiation, which may not provide ideal outcomes in some cases. In October 2023, at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 meeting, we presented the primary endpoint data from our AGENT IDE randomized controlled trial evaluating clinical outcomes in patients with ISR undergoing treatment with the AGENT DCB or conventional balloon angioplasty. The positive results in this primary analysis cohort supported the device’s U.S. Food and Drug Administration (FDA) approval, which we announced on March 1, 2024. Just a few months later, data from the full cohort of 600 patients were published in the Journal of the American Medical Association (JAMA) and shared in a late-breaking presentation at Cardiovascular Research Technologies (CRT) 2024 meeting.  (more…)
Heart Disease, Technology / 07.03.2024

Heart disease remains a leading cause of morbidity and mortality worldwide. Despite advances in medical technology and treatment modalities, managing heart disease remains challenging. This is particularly true in remote or underserved areas with limited access to specialized healthcare. However, remote patient monitoring (RPM) has transformed the landscape of cardiac care, offering innovative solutions for proactive management and early intervention. The market for remote patient monitoring was projected to be valued at $14.0 billion in 2023, according to PR Newswire. By 2028, it is anticipated to increase to $41.7 billion. This article explores the significance of remote patient monitoring in effectively managing heart disease and its evolving role in enhancing patient outcomes. (more…)
AHA Journals, Author Interviews, Biomarkers, Brigham & Women's - Harvard, Heart Disease / 27.02.2024

MedicalResearch.com Interview with: Rosangela Akemi Hoshi, Ph.D. Lemann Foundation Cardiovascular Research Postdoctoral Fellowship Center for Lipid Metabolomics Divisions of Preventive and Cardiovascular Medicine Brigham and Women's Hospital Boston, MA  MedicalResearch.com: What is the background for this study? Would you describe the IgG N-glycan profile? Response: Glycans are sugar coatings of proteins, made of monosaccharide building blocks, that are involved in a variety of biological pathways.  Different sugar structures can dictate or modify the protein’s activity through specific interactions with cellular receptors. For example, proteins lacking glycans have a reduced level or a complete loss of function. Glycans are of such importance that the 2022 Nobel Prize in chemistry was awarded for glycan-based science. In this study, we examined glycans attached to Immunoglobulins G (IgG) and their link with incidence of cardiovascular disease (CVD) due to their impact on IgG inflammatory properties. Since inflammation is not only a cause, but also an aggravating factor and a mediator of a worse prognosis in cardiometabolic disorders and CVD, we investigated whether different glycan structures may characterize an at-risk phenotype for CVD development. Determining glycan profiles involved in multiple conditions can serve prognostic and diagnostic purposes. Yet, unlike other types of macromolecules, glycans are still not as much explored, characterizing a promising but underappreciated class that should be further investigated. (more…)
Author Interviews, Heart Disease, NEJM / 18.01.2024

MedicalResearch.com Interview with: John Sapp MD FRCPC FHRSHeart Rhythm, Division of Cardiology QEII Health Sciences Centre Dalhousie University MedicalResearch.com: What is the background for this study? Response: Cardiac resynchronization is a robust therapy for heart failure in patients with ventricular dysfunction, left bundle branch block and left bundle branch block. It has been shown to improve heart failure status, symptoms, survival and reduce new onset ventricular arrhythmias for appropriate candidates. The RAFT study (NEJM 2010) enrolled patients with functional class II and III heart failure, wide QRS duration on ECG and reduced left ventricular ejection fraction, and demonstrated a reduction in heart failure hospitalization and mortality during a mean follow-up of 44 months. The long-term outcomes are not known. (more…)
AHA Journals, Author Interviews, Heart Disease, Kidney Disease, Obstructive Sleep Apnea, Sleep Disorders / 15.11.2023

MedicalResearch.com Interview with: Lead Author: Rupak Desai, MBBS Atlanta Veterans Affairs Medical Center Independent Researcher, Atlanta, GA, Presenter: Vamsikalyan Borra, MD Resident Physician, Internal Medicine University of Texas Rio Grande Valley, Weslaco, TX MedicalResearch.com: What is the background for this study? Response: The relationship between sleep apnea (OSA) and chronic kidney disease (CKD) is quite complex. OSA can cause hypoxia, activation of the sympathetic nervous system, and hypertension, all of which can have negative effects on kidney function. On the other hand, in patients with end-stage renal disease (ESRD), intensifying renal replacement therapy has shown some improvement in sleep apnea severity, suggesting a bi-directional relationship between the two conditions. While there are still uncertainties, recent studies have focused on understanding the interplay between OSA and CKD. The role of CPAP therapy, a common treatment for OSA, in relation to CKD is not yet clear. Observational studies present findings regarding the impact of CPAPs on kidney function. However, researchers are actively investigating its cardiovascular benefits and its influence on the progression of CKD. The objective of this study is to analyze the trends in composite cardiovascular events in hospital encounters among geriatric patients with CKD, comparing those with and without obstructive sleep apnea. Additionally, we are also investigating sex and racial disparities in trends of major adverse cardiovascular and cerebrovascular events (MACCE) among geriatric patients with obstructive sleep apnea (OSA). Furthermore, we are assessing the impact of continuous positive airway pressure (CPAP) treatment and dependence on MACCE outcomes in OSA patients (more…)
Author Interviews, Heart Disease, Stem Cells / 13.11.2023

MedicalResearch.com Interview with: Prof. Dr. Wolfram-Hubertus Zimmermann Director, Institute of Pharmacology and Toxicology University Medical Center Göttingen Georg-August University Göttingen, Germany   MedicalResearch.com: What is the background for this study? Response: Involvement in research and development in the field of tissue engineered heart repair since 25+ years. Bench-to-bed translation of our research. MedicalResearch.com: How are the stem cell obtained? Response: We make use of induced pluripotent stem cells as starting material to obtain heart muscle cells for the engineering of Engineered Human Myocardium (EHM) and its use as Biological Ventricular Assist Tissue (BioVAT). (more…)
Author Interviews, Heart Disease / 06.11.2023

MedicalResearch.com Interview with: Prakriti Gaba, MD Cardiovascular Medicine Fellow Brigham and Women's Hospital Deepak L. Bhatt MD MPH Director of Mount Sinai Fuster Heart Hospital Dr. Valentin Fuster Professor of Cardiovascular Medicine Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study?  Response: Accurate classification of acute myocardial infarction is instrumental for the appropriate diagnosis and effective management of patients suffering from this widely prevalent cardiovascular condition. In the past, there have been a variety of clinical scores published to advise clinicians on the best classifications schemes for patients with acute MI. These have included the Thrombolysis in Myocardial Infarction (TIMI) risk score, the HEART score, and the Killip classification. The strength of these traditional scores includes their practicality, as they can be implemented at the bedside to rapidly assist with prognostication. Nonetheless, as technologic advancements have made imaging and tissue identification more accessible, national and international committees are looking to revise traditional classification schemes of acute MI with novel ones leveraging multimodal approaches. (more…)
Heart Disease, Pediatrics / 06.10.2023

If you’re a worried or concerned parent looking to learn more about vascular ring, the following guide has information you need. This includes:
  • Vascular ring definition
  • Causes and symptoms
  • How the treatment of vascular ring works
By the end, you’ll be feeling much calmer with your new knowledge.

What Is Vascular Ring?

Vascular ring is a heart defect that’s present from birth. A part of the body’s main artery forms a small ring around the trachea (windpipe) or esophagus (the pipe that connects the throat to the stomach). In some cases, the ring can occur around both the trachea and the esophagus, but this is less common. Compared with other congenital heart defects, vascular ring is one of the rare ones. As of today, vascular rings are incredibly rare and occur in less than 1% of babies. (more…)
Author Interviews, Dermatology, Diabetes, Heart Disease, Weight Research / 28.08.2023

MedicalResearch.com Interview with: Dr. Alexis Elias Malavazos Endocrinology Unit Clinical Nutrition and Cardiovascular Prevention Service, IRCCS Policlinico Unit of Radiology, IRCCS Policlinico San Donato, San Donato Milanese, Italy   MedicalResearch.com: What is the background for this study? Response: Psoriasis is a systemic inflammatory disease often associated with obesity and type-2 diabetes (T2D). The inflammatory process of psoriasis can target adipose tissue depots, particularly those surrounding the heart and the coronary arteries, exposing them to an increased risk of cardiovascular disease. (more…)
Author Interviews, General Medicine, Health Care Systems, Heart Disease, JAMA / 26.06.2023

MedicalResearch.com Interview with: Dan P. Ly, MD, PhD, MPP Physician and an Assistant Professor Division of General Internal Medicine and Health Services Research David Geffen School of Medicine at UCLA MedicalResearch.com: What is the background for this study? Response: Cognitive biases, or ways of thinking that may deviate from rationality, are thought to influence physician decision-making, but there has been little large-scale evidence of their existence clinically. There is some large-scale evidence of the availability heuristic, under which the likelihood of an event is affected by how easily it comes to mind, but there’s little large scale evidence of other cognitive biases affecting physicians.  (more…)
Author Interviews, Heart Disease, JACC, Surgical Research / 22.05.2023

MedicalResearch.com Interview with: Aloke V. Finn MD Medical Director/Chief Scientific Officer CVPath Institute Inc. Gaithersburg, MD 20878   MedicalResearch.com: What is the background for this study? Response:Transcatheter left atrial appendageal closure (LAAC) has become an established therapeutic approach for prevention of stroke in subjects with non-valvular atrial fibrillation who are ineligible for long-term oral anticoagulation.  Device-related thrombus (DRT), developing after LAAO procedures occurs in a small proportion but patients receiving these devices but is associated with critical embolic events such as ischemic stroke. Thrombogenicity and delayed endothelialization of fabric play a role in the development of DRT.  Fluorinated polymers are known to have thromboresistant properties which may favorably modify blood biomaterial interactions of a LAAO device. In this study we compared the thrombogenicity and endothelial coverage (EC) after left atrial appendage occlusion (LAAO) between a novel fluoropolymer-coated Watchman (FP-WM (Watchman FLX PRO) and the conventional uncoated Watchman FLX (WM). (more…)
Author Interviews, Heart Disease, JAMA, Statins / 09.03.2023

MedicalResearch.com Interview with: Myeong-Ki Hong, MD PhD Professor of Cardiology Yonsei University College of Medicine Severance Cardiovascular Hospital Seoul, Korea MedicalResearch.com: What is the background for this study? Response: The background of this study was to compare the long-term clinical outcomes between the two distinct strategies regarding statin intensity in patients with coronary artery disease (CAD). One is to titrate statin intensity to meet a target low-density lipoprotein cholesterol (LDL-C) level (treat-to-target strategy), the other is to maintain high-intensity statin without a target goal (high-intensity statin strategy). (more…)
Author Interviews, Heart Disease, Race/Ethnic Diversity / 28.02.2023

MedicalResearch.com Interview with: Dr. Muchi Ditah Chobufo MD MPH Cardiology Fellow West Virginia University MedicalResearch.com: What is the background for this study? Response: Ischemic heart diseases are a significant cause of morbidity and mortality in the USA. Also, there exists alarming ethnic disparities in mortality rates following acute myocardial infarction. To this effect, significant efforts have been deployed over the years to curb its burden and reduce extant disparities. It is in this light that we set out to analyze general and ethnic specific trends in acute myocardial infarction related age adjusted mortality rates (AAMR) in the entire USA from 1999-2020.  (more…)
Author Interviews, Cost of Health Care, Heart Disease, JACC / 26.02.2023

MedicalResearch.com Interview with: Rishi K. Wadhera, MD, MPP, MPhil Section Head, Health Policy and Equity, Richard A. and Susan F. Smith Center for Outcomes Research Associate Program Director Cardiovascular Medicine Fellowship at Beth Israel Deaconess Medical Center Assistant Professor of Medicine, Harvard Medical School @rkwadhera MedicalResearch.com: What is the background for this study? Response: High and rising prescription drug costs in the United States contribute to medication non-adherence and financial strain among adults with cardiovascular risk factors or disease. As a result, addressing prescription drug costs in patients with chronic conditions has become a national priority. In response to these growing concerns, federal policymakers passed the Inflation Reduction Act on August 16, 2022, which aims to address high out-of-pocket drug costs for adults enrolled in Medicare Part D, by placing a $2000 annual cap on out-of-pocket prescription drug costs and expanding eligibility for full low-income subsidies to individuals that reduce deductible costs and prescription copayments (among several other provisions). It is unclear how these provisions will affect Medicare beneficiaries with cardiovascular risk factors and/or conditions. (more…)